ES2145122T3 - Compuestos antiproliferantes de 5-tiapirimidinona y 5-selenopirimidinona sustituidos. - Google Patents

Compuestos antiproliferantes de 5-tiapirimidinona y 5-selenopirimidinona sustituidos.

Info

Publication number
ES2145122T3
ES2145122T3 ES94904399T ES94904399T ES2145122T3 ES 2145122 T3 ES2145122 T3 ES 2145122T3 ES 94904399 T ES94904399 T ES 94904399T ES 94904399 T ES94904399 T ES 94904399T ES 2145122 T3 ES2145122 T3 ES 2145122T3
Authority
ES
Spain
Prior art keywords
compounds
selenopyrimidinone
thiapyrimidinone
antiproliferant
replaced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94904399T
Other languages
English (en)
Inventor
Judith G Deal
Michael D Varney
William H Romines
Cynthia L Palmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agouron Pharmaceuticals LLC
Original Assignee
Agouron Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals LLC filed Critical Agouron Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2145122T3 publication Critical patent/ES2145122T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE HAN DESCUBIERTOS NUEVOS DERIVADOS DE 5-TIA Y 5SELENOPIRIMIDINONA QUE INHIBEN LA TRANSFERASA DE FORMILO RIBONUCLEOTIDO DE ENZIMA (GARFT) Y TRANSFERASA DE FORMILO RIBONUCLEOTIDO DE CARBOXAMIDO DE IMIDAZOL (AICARFT). TAMBIEN SE PRESENTAN NUEVOS INTERMEDIOS DE ESTOS COMPUESTOS. TAMBIEN SE DESCRIBEN UN NUEVO METODO PARA PREPARAR TALES COMPUESTOS, ASI COMO METODOS Y COMPOSICIONES PARA EMPLEAR LOS COMPUESTOS COMO AGENTES ANTIPROLIFERATIVOS.
ES94904399T 1992-12-16 1993-12-10 Compuestos antiproliferantes de 5-tiapirimidinona y 5-selenopirimidinona sustituidos. Expired - Lifetime ES2145122T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99125992A 1992-12-16 1992-12-16

Publications (1)

Publication Number Publication Date
ES2145122T3 true ES2145122T3 (es) 2000-07-01

Family

ID=25537030

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94904399T Expired - Lifetime ES2145122T3 (es) 1992-12-16 1993-12-10 Compuestos antiproliferantes de 5-tiapirimidinona y 5-selenopirimidinona sustituidos.

Country Status (13)

Country Link
US (5) US5739141A (es)
EP (1) EP0674516B1 (es)
JP (1) JPH08504765A (es)
AT (1) ATE189390T1 (es)
AU (1) AU5846494A (es)
CA (1) CA2151588C (es)
DE (1) DE69327796T2 (es)
DK (1) DK0674516T3 (es)
ES (1) ES2145122T3 (es)
GR (1) GR3033314T3 (es)
PT (1) PT674516E (es)
SG (1) SG52739A1 (es)
WO (1) WO1994013295A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945427A (en) * 1995-06-07 1999-08-31 Agouron Pharmaceuticals, Inc. Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds
PT674516E (pt) 1992-12-16 2000-05-31 Agouron Pharma Compostos de 5-tiapirimidinona e 5-selenopirimidinona substituidos antiproliferativos
US5594139A (en) * 1993-01-29 1997-01-14 Agouron Pharmaceuticals, Inc. Processes for preparing antiproliferative garft-inhibiting compounds
RU2136686C1 (ru) * 1994-07-28 1999-09-10 Агурон Фармасьютикалз, Инк. Производные глутаминовой кислоты (варианты), фармацевтическая композиция, способ ингибирования роста и пролиферации клеток, производные тиофенкарбоновой кислоты (варианты)
CN1053448C (zh) * 1994-07-28 2000-06-14 阿格罗尼制药公司 用作抗增殖药物及garft抑制剂的化合物
US5608082A (en) * 1994-07-28 1997-03-04 Agouron Pharmaceuticals, Inc. Compounds useful as antiproliferative agents and GARFT inhibitors
US5831100A (en) * 1995-06-07 1998-11-03 Agouron Pharmaceuticals, Inc. Syntheses of optically pure compounds useful as GARFT inhibitors and their intermediates
AUPO227896A0 (en) * 1996-09-13 1996-10-03 Fujisawa Pharmaceutical Co., Ltd. Novel compounds and their preparation
NZ506779A (en) * 1998-03-27 2003-08-29 Genentech Inc Antagonists for treatment of cd11/cd18 adhesion receptor mediated disorders
ES2207277T3 (es) * 1998-09-04 2004-05-16 Agouron Pharmaceuticals, Inc. Compuestos utiles como inhibidores de aircraft.
US6423720B1 (en) 2001-02-01 2002-07-23 Duquesne University Of The Holy Ghost Pyrimidine compounds and methods for making and using the same
US20040043959A1 (en) * 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
EP2295976A1 (en) 2003-03-08 2011-03-16 Auvation Ltd Markers for colorectal cancer
CA2602291C (en) * 2005-03-28 2015-08-11 Pericor Therapeutics, Inc. Treatments for preventing or reducing adverse effects in a patient having decreased left ventricular function
US20070082859A1 (en) * 2005-10-07 2007-04-12 Stover Richard R Formulations of AICA riboside
WO2008086341A1 (en) * 2007-01-09 2008-07-17 Pericor Therapeutics, Inc. Methods. compositions, and formulations for preventing or reducing adverse effects in a patient
US8063033B2 (en) 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US7956051B2 (en) 2008-01-24 2011-06-07 Allergan, Inc. Therapeutic amides and related compounds
US7705001B2 (en) 2008-03-18 2010-04-27 Allergan, Inc Therapeutic substituted gamma lactams
KR20110028584A (ko) 2008-05-09 2011-03-21 알러간, 인코포레이티드 치료학적인 ｎ-아릴 또는 ｎ-헤테로아릴 피라졸리딘 및 피라졸리딘온 유도체
US7985765B2 (en) 2008-08-20 2011-07-26 Allergan, Inc. Therapeutic substituted pyrroles
JP5591245B2 (ja) * 2008-10-03 2014-09-17 ペリコー セラピューティクス， インコーポレイテッド 急性心不全の治療のための方法および組成物
US9090584B2 (en) * 2010-01-26 2015-07-28 Allergan, Inc. Therapeutic agents for treatment of ocular hypertension
WO2016089670A1 (en) * 2014-12-02 2016-06-09 Eli Lilly And Company 1 -oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as aicarft inhibitors in the treatment of cancers
DE102017221259A1 (de) * 2017-11-28 2019-05-29 Evonik Degussa Gmbh Silanmischungen und Verfahren zu deren Herstellung
CN112321425B (zh) * 2020-10-23 2022-08-09 上海毕得医药科技股份有限公司 一种4-(3-溴丙基)苯甲酸甲酯的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3222914A1 (de) * 1982-06-18 1983-12-22 Beiersdorf Ag, 2000 Hamburg Substituierte 5-phenylthio-6-amino-pyrimidinone, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen
GB8625019D0 (en) * 1986-10-18 1986-11-19 Wellcome Found Compounds
US4871743A (en) * 1988-01-19 1989-10-03 The Trustees Of Princeton University L-glutamic acid derivatives
JPH029869A (ja) * 1988-04-15 1990-01-12 Wellcome Found Ltd:The 新規化合物
US4971973A (en) * 1989-05-17 1990-11-20 Burroughs Wellcome Co. Glutamic acid derivatives
US4921836A (en) * 1989-05-17 1990-05-01 Burroughs Wellcome Co. Substituted glutamic acids
US4920125A (en) * 1989-08-29 1990-04-24 The Trustees Of Princeton University L-glutamic acid derivatives
US5013738A (en) * 1990-04-18 1991-05-07 The Trustees Of Princeton University L-glutamic acid derivatives
US5262385A (en) * 1990-07-24 1993-11-16 Mitsubishi Petrochemical Co., Ltd. Halogen-containing compounds, herbicidal composition containing the same as an active ingredient, and intermediary compounds therefor
US5945427A (en) 1995-06-07 1999-08-31 Agouron Pharmaceuticals, Inc. Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds
PT674516E (pt) 1992-12-16 2000-05-31 Agouron Pharma Compostos de 5-tiapirimidinona e 5-selenopirimidinona substituidos antiproliferativos
US5426110A (en) * 1993-10-06 1995-06-20 Eli Lilly And Company Pyrimidinyl-glutamic acid derivatives

Also Published As

Publication number Publication date
EP0674516A4 (es) 1995-10-25
CA2151588A1 (en) 1994-06-23
CA2151588C (en) 2002-03-19
EP0674516A1 (en) 1995-10-04
US6207670B1 (en) 2001-03-27
SG52739A1 (en) 1998-09-28
JPH08504765A (ja) 1996-05-21
WO1994013295A1 (en) 1994-06-23
ATE189390T1 (de) 2000-02-15
US20020173515A1 (en) 2002-11-21
PT674516E (pt) 2000-05-31
DE69327796T2 (de) 2000-06-21
US5726312A (en) 1998-03-10
US5739141A (en) 1998-04-14
EP0674516B1 (en) 2000-02-02
GR3033314T3 (en) 2000-09-29
US6323210B2 (en) 2001-11-27
DE69327796D1 (de) 2000-03-09
US20010018443A1 (en) 2001-08-30
AU5846494A (en) 1994-07-04
DK0674516T3 (da) 2000-07-24

Similar Documents

Publication Publication Date Title
ES2145122T3 (es) Compuestos antiproliferantes de 5-tiapirimidinona y 5-selenopirimidinona sustituidos.
BG101833A (bg) Гуаниново производно
ES2106965T3 (es) Nuevas 4-aza-5alfa-androstan-3-onas 7beta-sustituidas como inhibidores de 5alfa-reductasa.
DK0741694T3 (da) Phenyleddikesyrederivater, fremgangsmåder og mellemprodukter til deres fremstilling og midler indeholdende disse
IE840302L (en) 3-(5-aminopentyl)amino-1-benzazepin-2-one-1-alkanoic acids.
TR200003036T2 (tr) 12,13-Modifiye edilmiş epotilon türevleri
TW225534B (es)
TW327172B (en) Novel mercaptoacetylamide bicyclic lactam derivatives
DE69709938D1 (de) N-benzylpiperidin- und tetrahydropyridin-derivate
MY106202A (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof.
EP0975353A4 (en) PEPTIDYL-2-AMINO-1HYDROXYALKANESULPHONIC ACIDS AS CYSTEIN PROTEASE INHIBITORS
HU9500559D0 (en) New mercapto-acetamide tricyclic derivatives as enkephalinase-inhibitors
MX9801190A (es) Inhibidores de prolil endopeptidasa.
CA2166692A1 (en) Novel 9-n-bicyclic nucleoside agents useful as selective inhibitors of proinflammatory cytokines
CA2154668A1 (en) Condensed heterocyclic glutamic acid derivatives as antiproliferative agents
NO974155L (no) Ny fremgangsmåte for fremstilling av 2,3-dihydrobenzofuranolderivater
MX9603348A (es) Derivados de disulfuro de amida indano-2-mercaptoacetilica novedosos utiles como inhibidores de encefalinasa.
SG44827A1 (en) Compounds useful as antiproliferative agents and garft inhibitors
HU9201134D0 (en) Process for the production of an anti-metastatic substance
HUP0002727A2 (hu) Eljárás fibrinogén csökkentésére benzotiofénszármazékok felhasználásával
GR1001393B (el) Παράγωγα ιμιδαζο[2,1-Β] 3] βενζαζεπίνης, συν?έσεις και μέ?οδος χρήσεως.
MY127539A (en) Bridged indenopyrrolocarbazoles

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 674516

Country of ref document: ES